ArticleBreast cancer research and treatment2020
Sarcoma of the breast: breast cancer history as etiologic and prognostic factor-A population-based case-control study.
Article in Breast cancer research and treatment, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- Low overall survival after treatment for angiosarcoma: a single-centre retrospective observational cohort study of 64 patients.BMC cancer · 2025Observational
- Internal mammary node irradiation in early breast cancer - target coverage and implications on dose to organs at risk.Acta oncologica (Stockholm, Sweden) · 2025Article
- Complete remission in a rare pelvic angiosarcoma with liposomal doxorubicin: A comprehensive case report and review of literature.Rare tumors · 2025Article
- Rare Breast Cancers Review.Healthcare (Basel, Switzerland) · 2024Review
- Article
- Clinicopathological analysis and prognostic treatment study of angiosarcoma of the breast: a SEER population-based analysis.World journal of surgical oncology · 2023Article
- Breast Sarcomas-How Different Are They from Breast Carcinomas? Clinical, Pathological, Imaging and Treatment Insights.Diagnostics (Basel, Switzerland) · 2023Article
- Clinical Impact of Systemic Staging Studies in Secondary Breast Angiosarcoma.Surgery in practice and science · 2022Article
- Clinical and Molecular Insights of Radiation-Induced Breast Sarcomas: Is There Hope on the Horizon for Effective Treatment of This Aggressive Disease?International journal of molecular sciences · 2022Review
- Breast Primary Angiosarcoma: A Clinicopathologic and Imaging Study of a Series Cases.Breast cancer : basic and clinical research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSarcomas of the breast account for about 1% of all breast malignancies. The aim of this national survey was to explore etiologic and prognostic factors.
methodsUtilizing national Swedish registers, all patients registered with mesenchymal tumors in the breast during the period 1993-2013 (n = 344) were identified and compared to up to ten age and gender matched controls. Cancer history was retrieved for cases and controls. Conditional Poisson regression models were used for calculation of odds ratios.
resultsPrevious breast cancer was overrepresented among patients with angiosarcoma. The highest risk occurred ≥ 5 years after treatment for breast cancer (OR 73.9, 95% confidence interval, CI, 25.4-215; P < 0.001). An increase in incidence of angiosarcoma was observed during the study period (1.10, 95% CI 1.05-1.16; P < 0.001). The overall incidence of breast sarcoma increased from 1.52 to 2.04 cases per million per year. Angiosarcoma of the breast was associated with a significant excess mortality compared to age-matched controls (HR 4.65, 95% CI 3.01-7.19; P < 0.001).
conclusionsAngiosarcoma increased in incidence and displayed a more severe clinical course, with significantly shorter survival. The strong association between a history of breast cancer 5 years or more prior to the diagnosis of angiosarcoma points to radiotherapy as a contributing factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.